ISRCTN81314354进行中（未招募）不适用
Phase I trial: Parexel International Ltd. Code: 20628A
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
- 主要目的
- The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
排除标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
招募中
1 期
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid TumorNCT07275242Suzhou Suncadia Biopharmaceuticals Co., Ltd.107
招募中
1 期
A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese ParticipantsHealthy Volunteers (HV)NCT07525947Jade Biosciences, Inc.40
尚未招募
2 期
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic CancerNCT07301229Shanghai Henlius Biotech100
进行中（未招募）
2 期
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life 1HIV/AIDSPaediatricsPACTR202607574273305SERMAS Fundacion Hospital 12 de Octubre87
Enrolling By Invitation
1 期
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult ParticipantsUC - Ulcerative ColitisNCT07505030LyncBio Therapeutics Co., Ltd.50